Immunologic studies will be repeated more frequently if clinically indicated. Any abnormalities potentially related to treatment will be followed until they have resolved or have been determined not to be treatment-related. 4.1.1.1 All patients who are HLA A02 or A03 (approximately 50% of the US population) will undergo leukapheresis every 12 weeks while on-study when available and with the consent of the patient. Patients may refuse. IFN-gamma ELISPOT assay T cell proliferation Antibody Response Flow cytometry analysis of thymic emigrants Natural Killer (NK) Cells Regulatory T Cells Additional Assays: Blood samples may be used for additional research studies, which may include phenotypic and functional analysis of immune-cell subsets and analyses for cytokines, chemokines, antibodies, tumor associated antigens, anti-glycan antibodies and/or other markers. Details on these tests can be found in 4.1.2. 4.1.1.2 Collection of blood samples for immune assays: Blood samples may be obtained at baseline, 1 month, 3 months, 12 months, 18 months, then every 6 months at restaging while on study. All patients will have 6 (10ml) green top tubes and 2 (8ml) SST drawn prior to treatment at designated timepoints. 4.1.1.3 The samples will be processed at: Clinical Services Program NCI Frederick Cancer Research and Development Center PO Box B Frederick, MD 21702 301-846-1000 On days samples are drawn, Jennifer Bangh at CSP should be notified (phone: [301] 846-5893; fax [301] 846-6222). She will arrange courier delivery of the specimens to the processing lab. The weekly patient lists of samples drawn will be emailed to Caroline Jochems at jochemscm@mail.nih.gov, Jen Bangh at jb478s@nih.gov and Theresa Burks (burkst@mailnih.gov). 4.1.2 Immunological Assays 4.1.2.1 IFN-gamma ELISPOT We plan to examine the immune response in selected patients (HLA-A2-positive). HLA class I expression (HLA typing) with A2 subtyping will be done prior to enrollment.